Bush Tia L 4

What Happened
Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals (CNTA), had 8,549 shares withheld on Feb 1, 2026 to cover tax withholding obligations (treated as a disposition) at $24.57 per share for proceeds of $210,049. On Feb 2, 2026 she was granted awards totaling 175,000 units: 35,000 restricted share units (RSUs) and 140,000 derivative awards (reported as a grant/award).

Key Details

• Transactions:
  • Feb 1, 2026 — 8,549 shares withheld (F) at $24.57/share; proceeds reported $210,049 (tax withholding disposition).
  • Feb 2, 2026 — 35,000 RSUs granted (A) at $0.00 reported value.
  • Feb 2, 2026 — 140,000 derivative awards granted (A) at $0.00 reported value.
• Vesting / award terms:
  • The 35,000 RSUs are RSUs under the company plan; each RSU equals the right to one ordinary share and will vest/settle in four equal annual installments beginning Feb 2, 2027 (F3).
  • The 140,000 derivative award is subject to 1/48th vesting in equal monthly installments, with the first installment vesting on March 2, 2026 (F4).
• Other notes:
  • 8,549-share disposition was to satisfy tax withholding obligations (cashless withholding) (F2).
  • Ordinary shares may be represented by American Depositary Shares (ADS), each currently representing one ordinary share (F1).
  • Filing shows these transactions on Feb 1–2 and was filed on Feb 3, 2026; no late filing is indicated in the provided record.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.

Context
RSU grants are compensation awards that convert to actual shares only as they vest; they are not open-market purchases and do not necessarily signal buying interest. The withheld 8,549-share disposition is a routine administrative action to cover tax obligations related to vesting/settlement. The 140,000 derivative award’s monthly vesting schedule means portions will vest gradually beginning March 2026.